Company Announcements

In November, Nanomedical Diagnostics, a company driving the use of biosensor assays for life science research and diagnostics, named Dr. Joe Keegan, former president and CEO of ForteBio, to its Board.

In October, Luminex named Tadd S. Lazarus, MD, as senior vice president and CMO. Previously, he served as CMO at QIAGEN.

Innopsys named Applied Microarrays as a distributor in November.

In November, NanoString Technologies announced a new myeloid gene expression collaboration with the OHSU Knight Cancer Institute to create two new myeloid-focused research panels. The company is working with Lisa Coussens, PhD, professor and chair of the Developmental & Cancer Biology Department.

Quanterix announced in November a strategic collaboration with UmanDiagnostics, a company specializing in early detection of brain diseases, for access to a Simoa NeuroFilament Light assay.

Synoptics, a Scientific Digital Imaging business, named Dr. Brian Stammers as CEO in November. Most recently, he spent five years working as an international trade adviser for UK Trade & Investment.

In December, AYOXXA Biosystems announced that Rodney Turner was named permanent CEO. He was a senior corporate development executive at Life Technologies and has been a member of AYOXXA’s Board since 2014.

Gyros Protein Technologies appointed Abacus as its exclusive distributor of its immunoassay products in Australia and New Zealand.

SYGNIS entered into an agreement in December to acquire US-based C.B.S. Scientific for $900,000 in cash and stock. C.B.S. provides electrophoresis equipment, and scientific instrumentation for genomics and proteomics research. Its annual revenues total over $1.5 million, and it is profitable. SYGNIS expects the acquisitions to be earnings enhancing and cash generative immediately.

Product Introductions

In November, SCIENION introduced the sciREADER FL2 for fluorescence detection of multiplex assays, featuring three fluorescent channels. The company stated that “it’s the only reader on the market which allows for high quality imaging of 96-well plates for standard fluorescence single parameter assays and multiplexed assays.”

ProZyme launched in November the Gly-Q Glycan Analysis System for high-throughput glycoanalysis, combining sample preparation and detection. The capillary electrophoresis–based system is designed for use in biotherapeutic development and glycan biomarker discovery.

NanoString Technologies announced in November that it has begun accepting applications to its Technology Access Program for its Digital Spatial Profiling technology, which allows sequential analysis of multi-target IHC slides on a single slide.

In November, Optiscan released the second generation ViewnVivo miniaturized fluorescence endomicroscope platform for preclinical research.

In December, SGI-DNA launched the Custom Cloning Module for its BioXp 3200 System for synthesizing and cloning DNA directly into a vector of choice in an overnight run. Researchers can now add vectors for automated Gibson Assembly cloning from de novo–generated DNA fragments.

PathSensors introduced in December the new biosensor-based Bioflash MailGuard system for biothreat detection. It can detect more than 25 biological threats, including anthrax and ricin, in concentrations as low as 100 CFU in less than five minutes.